Abstracts Archive - Page 1237 of 2425 - ACR Meeting Abstracts

Abstract Number: 472 • 2017 ACR/ARHP Annual Meeting
Viral Hepatitis Influences Patient Reported Outcomes Measures in Rheumatoid Arthritis
Suraj Timilsina¹, Harlan Sayles², Bryant R. England³, James R. O'Dell⁴, Ted R. Mikuls⁵ and Kaleb Michaud², ¹Division of Rheumatology & Immunology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁵Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Viral hepatitis may complicate the treatment of RA since select DMARD have the potential to cause hepatotoxicity or reactivation of latent viral infections. Whether…
Abstract Number: 473 • 2017 ACR/ARHP Annual Meeting
Medication Utilization Patterns of Rheumatoid Arthritis Patients Receiving Anti-TNF Infusion in Community Rheumatology Practices in the United States: Will Differences in Dosing and Administration Efficiencies between Intravenous Golimumab and Infliximab Have a Cost Impact for Payers?
Sergio Schwartzman¹, Lorie A. Ellis², Dennis Parenti³, Shawn Black³, Stephen Xu⁴, Wayne Langholff⁴ and Shelly Kafka³, ¹Weill Cornell Medical College, New York, NY, ²Janssen HECOR Immunology, Horsham, PA, ³Janssen Scientific Affairs, LLC, Horsham, PA, ⁴Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: AWARE (Comparative and Pragmatic Study of Golimumab IV Versus Infliximab in Rheumatoid Arthritis) is an ongoing Phase 4 comparator study designed to provide a…
Abstract Number: 474 • 2017 ACR/ARHP Annual Meeting
Comparison of Tofacitinib Efficacy in Patients with Moderate Vs Severe Rheumatoid Arthritis: Pooled Analysis of Phase 3 Studies
Sergio Schwartzman¹, Prashanth Sunkureddi², Liza Takiya³, Mark Snyder³, Haiyun Fan⁴, Tatjana Lukic⁵, Jacqui Roberts⁶ and William F C Rigby⁷, ¹Hospital for Special Surgery, New York, NY, ²Clear Lake Rheumatology, Nassau Bay, TX, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶Pfizer Inc, Tadworth, United Kingdom, ⁷Geisel School of Medicine at Dartmouth, Lebanon, NH
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We evaluated tofacitinib 5 and 10 mg twice daily (BID)…
Abstract Number: 475 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patient Characteristics Also Predict Response to Therapy with Biologic Agents: Results from the Corrona Certain Study
Dimitrios A. Pappas¹, James Murray², Carol J. Etzel¹, David R Nelson², Bernice Gershenson³, Katherine C. Saunders¹, Sabrina Rebello¹ and Joel Kremer⁴, ¹Corrona, LLC, Southborough, MA, ²Eli Lilly and Company, Indianapolis, IN, ³University of Massachusetts Medical School, Worcester, MA, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Response to biologic agents approved for RA may be associated with patient reported factors that are not related to disease and usually not included…
Abstract Number: 476 • 2017 ACR/ARHP Annual Meeting
Novel Interaction between Anti-Citrulline Monoclonal Antibodies and Apoptotic Cells Is Mediated through Citrullinated Nuclear Antigens
Katy A. Lloyd¹, Peter Sahlström², Johanna Steen¹, Philip J. Titcombe^3,4, Diana Zhou¹, Christina Lundqvist⁵, Olov Ekwall^6,7, Jimmy Ytterberg¹, Johan Rönnelid⁸, Daniel L. Mueller³, Lars Klareskog¹, Vivianne Malmström¹ and Caroline Grönwall⁹, ¹Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ²Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ³Dept. of Medicine, University of Minnesota Medical School, Minneapolis, MN, ⁴Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Sweden, Sweden, ⁵Dept. of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden, ⁶Dept. of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy University of Gothenburg, Göteborg, Sweden, ⁷Dept of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden, ⁸Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁹Dep. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) display broad cross-reactivities and target proteins including a-enolase, filaggrin, vimentin, fibrinogen, and histones. However, every monoclonal ACPA has a distinct…
Abstract Number: 477 • 2017 ACR/ARHP Annual Meeting
Monoclonal ACPA-IgG Feature Extensive Fab Glycosylation
Katy A. Lloyd¹, Johanna Steen¹, Philip J. Titcombe^2,3, Khaled Amara⁴, Diana Zhou¹, Lena Israelsson⁵, Susanna L. Lundström⁶, Daniel L. Mueller³, Lars Klareskog¹, Vivianne Malmström¹ and Caroline Grönwall⁷, ¹Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ²Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Sweden, Sweden, ³Dept. of Medicine, University of Minnesota Medical School, Minneapolis, MN, ⁴Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁵Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁶Dept. of Medical Biochemistry and Biophysics, Division of Physiological Chemistry, Karolinska Institutet, Stockholm, Sweden, ⁷Dep. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Fab-glycosylation is found in ~15-25% serum IgG and while its exact consequence remains unknown, it may alter IgG functionality. Recent data revealed elevated Fab-glycosylation…
Abstract Number: 478 • 2017 ACR/ARHP Annual Meeting
Ectopic Lymphoid Tissue in the Lung Is Uniquely Associated with the ACPA IgA Isotype Even in Absence of Classifiable RA
Lindsay B. Kelmenson¹, M. Kristen Demoruelle¹, Carlyne D. Cool² and Kevin D. Deane¹, ¹Rheumatology Division, University of Colorado Denver, Aurora, CO, ²Pathology, University of Colorado Denver, Aurora, CO
Background/Purpose: Antibodies to citrullinated protein antigens (ACPA) precede the development of rheumatoid arthritis (RA) and may be generated in the lung of established and preclinical…
Abstract Number: 479 • 2017 ACR/ARHP Annual Meeting
Protein Carbamylation Is Induced By Activated Neutrophil: Ex Vivo Analysis
Shuichiro Nakabo¹, Koichiro Ohmura¹, Shuji Akizuki¹, Nobuo Kuramoto¹, Kosaku Murakami², Ran Nakashima², Motomu Hashimoto³, Hajime Yoshifuji¹, Masao Tanaka³ and Tsuneyo Mimori¹, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Clinical Immunology and Rheumatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ³Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Protein carbamylation is induced by activated neutrophil: ex vivo analysisBackground/Purpose: Anti-carbamylated protein (anti-CarP) antibodies were reported to be detected in 45% of rheumatoid arthritis (RA)…
Abstract Number: 480 • 2017 ACR/ARHP Annual Meeting
ANTI-Carbamylated Protein Antibodies (CARP) in Palindromic Rheumatism: Prevalence and Clinical Significance
Raul Castellanos-Moreira Sr.¹, Virginia Ruiz-Esquide¹, María José Gomara², Sonia Cabrera-Villalba¹, Sebastian C Rodriguez-Garcia¹, Georgina Salvador³, Andrea Cuervo¹, Julio Ramírez¹, M. Victoria Hernández¹, Juan Cañete¹, Isabel Haro² and Raimon Sanmartí¹, ¹Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ²Unit of Synthesis and Biomedical Applications of Peptides, IQAC-CSIC, Barcelona, Spain, ³Hospital Universitario Mutua Terrassa, Barcelona, Spain
Background/Purpose: Autoantibodies (RF or ACPA) are found in sera from patients with palindromic rheumatism (PR) but there are no studies analyzing the presence of Anti-carbamylated…
Abstract Number: 481 • 2017 ACR/ARHP Annual Meeting
Immunocompetent Cells Expressing Citrullinated Proteins in Joint Synovium of Osteoarthritis and Rheumatoid Arthritis
Kyoko Honne¹, Masahiro Iwamoto², Shunichiro Hanai¹, Satoshi Machida³, Hitoshi Sekiya⁴, Reina Tsuda⁵, Tatsuhiko Ozawa⁵, Tadayoshi Karasawa⁶, Atsushi Muraguchi⁵, Masafumi Takahashi⁶, Hiroyuki Kishi⁵ and Seiji Minota⁷, ¹Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke, Japan, ²Deivision of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke, Japan, ³Department of Orthopaedic Surgery, Orthopedics Clinic Medical Papas, Tochigi, Japan, ⁴Department of orthopedic surgery, Jichi Medical University, Shimotsuke, Japan, ⁵Department of Immunology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan, ⁶Division of Inflammation Research Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Japan, ⁷Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan
Background/Purpose: Human monoclonal ACPA (Human-ACPA) is reported to strongly bind to synovium in RA patients [1]. The aims of our study were 1) To investigate…
Abstract Number: 482 • 2017 ACR/ARHP Annual Meeting
The Link between ACPA and Erosion Development: Is ACPA Sufficient? an Association Study in Clinically Suspect Arthralgia
Robin M ten Brinck¹, REM Toes² and Annette H.M. van der Helm-van Mil¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) associate with more severe joint erosions in rheumatoid arthritis (RA), but the underlying mechanism is unclear. Recent in vitro and…
Abstract Number: 483 • 2017 ACR/ARHP Annual Meeting
Anti-Peptidylarginine Deiminase-4 Antibodies Are Present in the Sputum of RA Patients and Can Activate Peptidylarginine Deiminase-4 Enzyme Activity
M. Kristen Demoruelle¹, Hong Wang², Ryan L. Davis², A. Itzam Marin¹, Jill M. Norris³, V. Michael Holers¹, Kevin D. Deane¹ and Erika Darrah², ¹Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²Division of Rheumatology, The Johns Hopkins University, Baltimore, MD, ³Department of Epidemiology, Colorado School of Public Health, Aurora, CO
Background/Purpose: Anti-peptidylarginine deiminase (PAD)-4 antibodies (Abs) are present in a portion of RA patients and associate with more severe joint disease, suggesting that they play…
Abstract Number: 484 • 2017 ACR/ARHP Annual Meeting
Sputum Neutrophils Demonstrate Increased Neutrophil Extracellular Trap Formation in RA-Free Subjects at-Risk of Future RA
Yuko Okamoto¹, Michael P. Mohning², Stacey M. Thomas², Ashley Visser¹, Lindsay B. Kelmenson³, Jill M. Norris⁴, Mariana J. Kaplan⁵, William J. Janssen², V. Michael Holers¹, Kevin D. Deane¹ and M. Kristen Demoruelle¹, ¹Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²Division of Pulmonary Disease and Critical Care Medicine, National Jewish Health, Denver, CO, ³Division of Rheumatoloty, University of Colorado School of Medicine, Aurora, CO, ⁴Department of Epidemiology, Colorado School of Public Health, Aurora, CO, ⁵Systemic Autoimmunity Branch, NIAMS/NIH, Bethesda, MD
Background/Purpose: Data support that ACPAs are generated in the lung in RA-free subjects At-Risk of future RA. Our group previously demonstrated a significant positive correlation…
Abstract Number: 485 • 2017 ACR/ARHP Annual Meeting
Different Citrullination Profiles in Spontaneous Versus Leukemia-Associated Rheumatoid Arthritis
Tal Gazitt¹, Son Hong Nguyen², Ari Salinger², Christian Lood³, Xizhang Sun¹, Lena M. Tanaka¹, David Feith⁴, Jeffrey Ledbetter⁵, Gordon Starkebaum⁶, Thomas Loughran Jr.⁷, Paul R. Thompson² and Keith B. Elkon⁸, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA, ³Division of Rheumatology, Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, ⁴Hematology and Oncology, University of Virginia, Charlottesville, VA, ⁵University of Washington, Seattle, WA, ⁶Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA, ⁷Hematology Oncology, University of Virginia, Charlottesville, VA, ⁸Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA
Background/Purpose: Protein citrullination, the post-translational conversion of arginine to citrulline, mediated by peptidylarginine deiminase (PAD) enzymes, is considered a likely mechanism for the stimulation of…
Abstract Number: 486 • 2017 ACR/ARHP Annual Meeting
Anti-Citrullinated Protein Antibody Reactivities in Treatment NaïVe Early Rheumatoid Arthritis
Maria K. Jonsson^1,2, Aase Hensvold³, Monika Hansson⁴, Linda Mathsson-Alm⁵, Anna-Birgitte Aga², Joseph Sexton², Bjørg-Tilde Fevang^1,6, Siri Lillegraven², Anca I. Catrina³ and Espen A. Haavardsholm^2,7, ¹Dept. of Rheumatology, Haukeland University Hospital, Bergen, Norway, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Karolinska Institute, Stockholm, Sweden, ⁴Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ⁵Thermo Fisher Scientific, Uppsala, Sweden, ⁶Dept. of Clinical Science, University of Bergen, Bergen, Norway, ⁷University of Oslo, Oslo, Norway
Background/Purpose: Anti-citrullinated protein antibody (ACPA) reactivities can precede RA onset, and may be involved in the pathogenesis of the disease. We wanted to assess the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].